These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 36074406)

  • 1. Differential Proteomic and Genomic Comparison of Resistance Mechanism of Pseudomonas aeruginosa to Cefoperazone Sodium/Sulbactam Sodium.
    Cai S; Zhang K; Wei F; Yang L; Song D; Luo J; Huang H; Gao X; DU G; Kong J; Chen Y
    An Acad Bras Cienc; 2022; 94(3):e20211160. PubMed ID: 36074406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergy of gatifloxacin with cefoperazone and cefoperazone-sulbactam against resistant strains of Pseudomonas aeruginosa.
    Sivagurunathan N; Krishnan S; Rao JV; Nagappa AN; Subrahmanyam VM; Vanathi BM
    J Med Microbiol; 2008 Dec; 57(Pt 12):1514-1517. PubMed ID: 19018022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Changes of antimicrobial resistance among nonfermenting gram-negative bacilli isolated from intensive care units from 1994 to 2001 in China].
    Wang H; Chen MJ;
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):385-90. PubMed ID: 12820914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Error rates in cefoperazone and cefoperazone-sulbactam disk tests with Enterobacteriaceae and Pseudomonas aeruginosa.
    Hardy DJ; Barry AL; Fuchs PC; Gerlach EH; McLaughlin JC; Pfaller MA
    Eur J Clin Microbiol Infect Dis; 1992 Oct; 11(10):926-30. PubMed ID: 1486889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of inoculum size on the activity of cefoperazone-sulbactam against multidrug resistant organisms.
    Chang PC; Chen CC; Lu YC; Lai CC; Huang HL; Chuang YC; Tang HJ
    J Microbiol Immunol Infect; 2018 Apr; 51(2):207-213. PubMed ID: 29037802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nitrite Promotes ROS Production to Potentiate Cefoperazone-Sulbactam-Mediated Elimination to Lab-Evolved and Clinical-Evolved Pseudomonas aeruginosa.
    Kuang SF; Li X; Feng DY; Wu WB; Li H; Peng B; Peng XX; Chen ZG; Zhang TT
    Microbiol Spectr; 2022 Aug; 10(4):e0232721. PubMed ID: 35863024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of drug resistance of Pseudomonas aeruginosa and use of antibiotics in burn wards during 6 years].
    Dou Y; Zhang Q
    Zhonghua Shao Shang Za Zhi; 2014 Feb; 30(1):9-14. PubMed ID: 24684983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro susceptibility of cefoperazone-susceptible and -resistant gram-negative rods to cefoperazone plus sulbactam, other beta-lactams, aminoglycosides and quinolone.
    Chandrasekar PH; Sluchak JA
    Infection; 1991; 19(1):49-53. PubMed ID: 2013510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefoperazone/sulbactam: New composites against multiresistant gram negative bacteria?
    Ku YH; Yu WL
    Infect Genet Evol; 2021 Mar; 88():104707. PubMed ID: 33418147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013-2014).
    Pfaller MA; Flamm RK; Duncan LR; Mendes RE; Jones RN; Sader HS
    Diagn Microbiol Infect Dis; 2017 Jun; 88(2):177-183. PubMed ID: 28341098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Combined effect of sulbactam/cefoperazone and other antibiotics against clinical isolates of multi-resistant strains. II. In vitro combined effects of sulbactam/cefoperazone with imipenem/cilastatin, cefuzonam, flomoxef, amikacin or tobramycin].
    Kouda M; Kumagai I; Kobayashi J; Sugai R; Matsuzaki H
    Jpn J Antibiot; 1991 Feb; 44(2):130-9. PubMed ID: 2041154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicentre study on antibiotic susceptibilities of anaerobic bacteria to cefoperazone-sulbactam and other antimicrobial agents.
    Clark RB; Bartelt MA; Chan EL; Dalton HP
    J Antimicrob Chemother; 1992 Jan; 29(1):57-67. PubMed ID: 1737725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of cefoperazone-sulbactam combinations against cefoperazone-resistant clinical bacterial isolates.
    Eliopoulos GM; Klimm K; Ferraro MJ; Moellering RC
    Eur J Clin Microbiol Infect Dis; 1989 Jul; 8(7):624-6. PubMed ID: 2506024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combined effect of sulbactam/cefoperazone and other antibiotics against clinical isolates of multi-resistant strains. I. Effect of sulbactam against beta-lactams resistant strains and in vitro combined effect of sulbactam/cefoperazone with each of piperacillin, latamoxef, ceftazidime, fosfomycin and doxycycline].
    Kouda M; Kumagai I; Kobayashi J; Sugai R; Matsuzaki H
    Jpn J Antibiot; 1990 Apr; 43(4):636-58. PubMed ID: 2199689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative in-vitro activity of cefoperazone/sulbactam and 11 other agents against multidrug resistant Bacteroides fragilis group species.
    Goldstein EJ; Citron DM
    J Antimicrob Chemother; 1996 Oct; 38(4):733-7. PubMed ID: 8937969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amikacin and cefoperazone/sulbactam alone or in combination against carbapenem-resistant Pseudomonas aeruginosa.
    Cai Y; Yang D; Wang J; Wang R
    Diagn Microbiol Infect Dis; 2018 Jun; 91(2):186-190. PubMed ID: 29486972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In vitro resistance development in Acinetobacter baumannii to sulbactam and cefoperazone].
    Wieczorek P; Sacha P; Ojdana D; Milewski R; Jurczak A; Kaczyńska K; Tryniszewska E
    Med Dosw Mikrobiol; 2012; 64(1):55-62. PubMed ID: 22808730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [In vitro antibacterial activity of sulperazone on multi-resistant strains of bacteria from burn wounds].
    Xu W; Chen X
    Zhonghua Wai Ke Za Zhi; 1995 Jul; 33(7):390-2. PubMed ID: 8565723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of cefoperazone-sulbactam combination against gram negative bacilli.
    Poudyal N; Gyawali N; Gurung R; Bhattarai NR; Baral R; Khanal B; Shrestha S; Amatya R; Bhattacharya SK
    Nepal Med Coll J; 2012 Mar; 14(1):5-8. PubMed ID: 23441486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of the distribution characteristics and drug resistance of non-fermenting bacterial infection in intensive care unit from 2009 to 2015].
    Hao D; Hu Z; Liu X; Sun T; Wang T; Tian H; Wang X
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2016 May; 28(5):439-44. PubMed ID: 29920041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.